Immuno-Biological Laboratories Co Ltd

Immuno-Biological Laboratories maintains a strong liquidity position with a current ratio of 4.94 and cash and equivalents of ¥825.73 million, which is significantly higher than the industry median. The company's liquidity FPT (free cash flow to total liabilities) is 0.62, indicating a robust ability to meet short-term obligations. The debt-to-equity ratio of 0.13 is well below the industry median, suggesting a conservative capital structure with minimal leverage risk. Profitability metrics show a return on equity (ROE) of 16.45% and a return on assets (ROA) of 13.5%, both exceeding the industry median for pharmaceuticals. The gross margin of 65.4% and operating margin of 21.6% are also above the sector average, indicating efficient cost management and pricing power. Net income of ¥249.05 million reflects strong profitability relative to revenue of ¥969.53 million. The company's revenue is distributed across four segments: Diagnostic and Reagent, Genetically Modified Silkworm, Testing, and Cosmetics. The Diagnostic and Reagent segment is the largest contributor, with no single geographic region accounting for more than 30% of total revenue, suggesting a diversified geographic exposure. The Testing segment is the fastest-growing, with a 12.3% YoY revenue increase, driven by demand for lipid metabolism analysis technology. Looking ahead, the company is projected to grow revenue by 4.5% in the current fiscal year and 3.2% in the next, with operating income expected to increase by 2.8% and 1.9%, respectively. This growth is supported by a stable capital structure and strong cash flow generation. The company's free cash flow of ¥204.81 million and operating cash flow of ¥183.49 million provide flexibility for reinvestment or shareholder returns. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no near-term dilution pressure, and the dilution potential is low, as shares outstanding remain unchanged between basic and diluted measures. The conservative capital structure and strong cash position mitigate credit risk, and the company's ROE and ROA suggest a strong economic moat. Recent events include the continued expansion of the Testing segment and the development of new pharmaceutical raw materials in the Genetically Modified Silkworm segment. No material regulatory or geopolitical risks were identified in the latest filings, and the company remains focused on innovation and market expansion.